Xenon Pharmaceuticals (XENE) News Today

Xenon Pharmaceuticals Inc. (NASDAQ: XENE) has seen mixed analyst actions and a key clinical milestone over the past 24–36 hours, contributing to today’s stock movement. Below is a summary of recent developments.

• Positive Sentiment: Chardan Capital reiterated its Buy rating on XENE and maintained a $55.00 price objective.Xenon Pharmaceuticals' (XENE) "Buy" Rating Reiterated at Chardan Capital
• Positive Sentiment: TD Cowen reaffirmed its Buy rating on XENE, underscoring confidence in the company’s pipeline.TD Cowen Reaffirms Their Buy Rating on Xenon (XENE)
• Positive Sentiment: XENE shares gapped up following an analyst upgrade, reflecting renewed buy-side enthusiasm.Xenon Pharmaceuticals (NASDAQ:XENE) Shares Gap Up After Analyst Upgrade
• Positive Sentiment: Wedbush raised its price target on XENE to $43.00 and kept an Outperform rating.Xenon Pharmaceuticals (NASDAQ:XENE) Given New $43.00 Price Target at Wedbush
• Positive Sentiment: Leerink Partners revised its Q3 2025 EPS forecast for XENE upward to ($1.14) from ($1.16), showing incremental improvement in near-term expectations. Leerink Partners Q3 2025 EPS Revision
• Positive Sentiment: Xenon announced completion of patient recruitment for its Phase 3 study, advancing its lead program toward key readouts.Xenon Completes Patient Recruitment for Phase 3 Study
• Negative Sentiment: Cantor Fitzgerald cut its FY 2025 EPS estimate for XENE to ($3.85) from ($3.43), signaling more conservative full-year expectations. Cantor Fitzgerald FY 2025 EPS Revision
• Negative Sentiment: HC Wainwright slightly lowered its Q3 2025 EPS forecast for XENE to ($1.26) from ($1.25), though it kept a Buy rating and $53 target. HC Wainwright Q3 2025 EPS Revision
• Negative Sentiment: William Blair trimmed its Q3 2025 EPS view for XENE to ($1.20) from ($1.07), despite maintaining an Outperform rating. William Blair Q3 2025 EPS Revision
• Negative Sentiment: William Blair’s initial FY 2027 EPS forecast for XENE came in at ($5.55), notably below the current consensus of ($3.10). William Blair FY 2027 EPS Estimate
• Negative Sentiment: Royal Bank of Canada lowered its price target on XENE from $57.00 to $55.00, while keeping an Outperform rating. RBC Lowers Expectations for Xenon Pharmaceuticals Stock Price